BioSpace News Archive

Business

Atomwise and OncoStatyx Announce Joint Venture to Develop Small Molecule Inhibitors of Oncology Target KDM5B

Atomwise, Inc. announced the launch of a joint venture with OncoStatyx, LLC, an oncology focused preclinical stage biotechnology company based in Ohio.

September 10, 2019
·
3 min read
Drug Development

AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

AVEO Oncology announced results from the second prespecified analysis of overall survival in the TIVO-3 trial.

September 10, 2019
·
10 min read
Ontario Lung Association unmasks the risks of cannabis on lung health

The campaign was made possible by funding from Health Canada, encouraging young adults to follow the misguided adventures of a not-so-superhero called “The Toker”

September 10, 2019
·
2 min read
BioMidwest

Michigan-based Memorial Healthcare: First in U.S. to use new Neurofilament Light Chain technology for multiple sclerosis patients

Innovative new NfL tests may help predict disease course in neurological conditions

September 10, 2019
·
4 min read
Business

Lasker Foundation Announces 2019 Lasker Awards For Basic And Clinical Medical Research And Public Service

The Lasker Foundation today announced the winners of its 2019 Lasker Awards

September 10, 2019
·
6 min read
Business

American Cancer Society Relay For Life Celebrates Its 35th Anniversary

With more than 3,500 events worldwide the Relay For Life movement continues to be the largest peer-to-peer fundraising event to achieve a world without cancer

September 10, 2019
·
2 min read
IASLC World Conference on Lung Cancer--Summary of the Presidential Symposium Research

Lung cancer screening model favored in Europe detects more cancers than one preferred in the United States

September 10, 2019
·
9 min read
Drug Development

Phase I Study of “Off-The-Shelf” Virus-Specific T Cells Published in BLOOD ADVANCES

Research published in the journal BLOOD ADVANCES established the feasibility of using a small bank of third-party cell lines generated from carefully chosen donors to provide virus-specific T-cell therapy to a large number of patients.

September 10, 2019
·
5 min read
Drug Development

Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers

These clinical data are consistent with the findings from numerous pre-clinical studies.

September 10, 2019
·
8 min read
Biotech Bay

Ablacon Announces Release of New and Improved Ablamap Technology Under Existing CE Mark

New Version to Be Used in the Randomized FLOW-AF Clinical Study

September 10, 2019
·
2 min read